Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858450 · ClinicalTrials.gov registry record
This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 3,442,996
- Enrollment target
NCT05858450 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 3,442,996 participants.
The verdict
NCT05858450 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 3,442,996 participants
- Enrollment target
Study Summary
This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.
Interventions
- BIOLOGICAL Quadrivalent Influenza Vaccine
- BIOLOGICAL Comirnaty
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,442,996 participants |
| Start Date | 2023-05-05 |
| Est. Completion | 2023-05-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05858450
The ClinicalTrials.gov registry entry for NCT05858450 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,442,996 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Quadrivalent Influenza Vaccine is the first listed.
NCT05858450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05858450 about?
NCT05858450 is a clinical study titled "This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.". This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.
What is the current status of trial NCT05858450?
This trial is currently completed. The enrollment target is 3,442,996 participants. The study started on 2023-05-05. Estimated completion is 2023-05-12.
What interventions are being tested in trial NCT05858450?
The interventions under investigation include: Quadrivalent Influenza Vaccine (BIOLOGICAL), Comirnaty (BIOLOGICAL).
Who is sponsoring clinical trial NCT05858450?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.